Carol Shields, MD
Ophthalmology · Philadelphia, PANPI 1578652988
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,000 of the $26,687 with a category attached, or 82.4%. Carl Zeiss Meditec, Inc. accounts for 75.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $13,150 and has fallen 99.8% since, to $32 in 2025. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 9 payments — averaging $2965.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$20K
- Glaukos Corporation$5K
- AbbVie$1K
- Eyepoint US, Inc.$750
- Alcon$55
Across 1 payment — averaging $668.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Carl Zeiss Meditec, Inc.$669
What the payments were for
- Consulting fees$22,00082%
- Speaking & faculty fees$4,61617%
- Food & beverage$710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 3 | $20,150 |
| Glaukos Corporation | 1 | $4,616 |
| AbbVie(2 entities) | 2 | $1,116 |
| Eyepoint US, Inc. | 1 | $750 |
| Alcon | 2 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clarus 700$13,150
- CLARUS$4,000
- OZURDEX$1,100
- DEXYCU$750
How this compares
$26,687 in reported general payments places this provider in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 262 | $2,868 |
| Atropine Sulfate | 97 | $2,493 |
| ErythromycinErythromycin Base | 60 | $615 |
| Ondansetron OdtOndansetron | 61 | $448 |
| BetadinePovidone-Iodine | 13 | $209 |
| Tetracaine HclTetracaine Hcl/Pf | 12 | $124 |
| Kenalog-40Triamcinolone Acetonide | 11 | $96 |
| Lorazepam | 40 | $82 |
| Ondansetron Hcl | 23 | $75 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Philadelphia
- Julia HallerPhiladelphia$1.5M
- Beeran MeghparaPhiladelphia$496K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
- Anton KolomeyerPhiladelphia$355K
- Durga BorkarPhiladelphia$150K
- Rachel NiknamPhiladelphia$142K
- Joseph MarkoffPhiladelphia$130K
- Leslie KatzPhiladelphia$105K
- Zeba SyedPhiladelphia$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.